Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.

<h4>Background</h4>Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven. Antiviral combinations have not been systematically studied. We aimed...

Full description

Saved in:
Bibliographic Details
Main Authors: David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Joseph F Standing, FLARE Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-10-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004120&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004120&type=printable

Similar Items